Long‐Term Follow Up in Anti‐Contactin‐1 Autoimmune Nodopathy
Annals of Neurology · 2025
DOI: 10.1002/ana.27142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, 2025. Verfasst von Marta Caballero-Ávila und 46 weiteren Autor:innen. Beteiligte Einrichtung: Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Sant Pau Biomedical Research Institute (IIB Sant Pau), Un…. Hauptthemen laut MEDLINE: Autoantibodies, Contactin 1, Autoimmune Diseases of the Nervous System. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: GBS-CIDP Fundation Benson Fellowship, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Objective
To analyze long‐term clinical and biomarker features of anti‐contactin‐1 (CNTN1) autoimmune nodopathy (AN).
Methods
Patients with anti‐CNTN1 + autoimmune nodopathy detected in our laboratory from which clinical information was available were included. Clinical features and treatment response were retrospectively collected. Autoantibody, serum neurofilament light chain (sNfL), and serum CNTN1 levels (sCNTN1) were analyzed at baseline and follow up.
Results
A total of 31 patients were included. Patients presented with progressive sensory motor neuropathy (76.7%) with proximal (74.2%) and distal involvement (87.1%), ataxia (71.4%), and severe disability (median INCAT at nadir of 8). A total of 11 patients (35%) showed kidney involvement. Most patients (97%) received intravenous immunoglobulin, but only 1 achieved remission with intravenous immunoglobulin. A total of 22 patients (71%) received corticosteroids, and 3 of them (14%) did not need further treatments. Rituximab was effective in 21 of 22 patients (95.5%), with most of them (72%) receiving a single course. Four patients (12.9%) relapsed after a median follow up of 25 months after effective treatment (12–48 months). Anti‐CNTN1 titers correlated with clinical scales at sampling and were negative after treatment in all patients, but 1 (20/21). sNfL levels were significantly higher and sCNTN1 significantly lower in anti‐CNTN1 + patients than in healthy controls (sNfL: 135.9 pg/ml vs 7.48 pg/ml, sCNTN1: 25.03 pg/ml vs 22,186 pg/ml, p < 0.0001). Both sNfL and sCNTN1 returned to normal levels after successful treatment.
Interpretation
Patients with anti‐CNTN1 + autoimmune nodopathy have a characteristic clinical profile. Clinical and immunological relapses are infrequent after successful treatment, suggesting that continuous treatment is unnecessary. Anti‐CNTN1 antibodies, sNfL, and sCNTN1 levels are useful to monitor disease status in these patients. ANN NEUROL 2025;97:529–541
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Sant Pau Biomedical Research Institute (IIB Sant Pau), Universitat Autònoma de Barcelona, Barcelona, Spain.
- Department of Neurology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.
- Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, Amsterdam UMC, Amsterdam, the Netherlands.
- Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
- Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Neurology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.
ORCID-Profile: Marta Caballero-Ávila, Lorena Martín-Aguilar, Elba Pascual-Goñi, Romana Höftberger, Thais Armangué, Álvaro Carbayo, Davide Sparasci, Cinta Lleixà
Förderung
- GBS-CIDP Fundation Benson Fellowship
- Instituto de Salud Carlos III
Zitieren
APA
Caballero-Ávila, M., Martín-Aguilar, L., Pascual-Goñi, E., Michael, M. R., Koel-Simmelink, M. J. A., Höftberger, R., Wanschitz, J., Alonso-Jiménez, A., Armangué, T., Baars, A. E., Carbayo, Á., Castek, B., Collet-Vidiella, R., De Winter, J., Del Real, M. Á., Delmont, E., Diamanti, L., Doneddu, P. E., Hiew, F. L., …, & Querol, L. (2025). Long‐Term Follow Up in Anti‐Contactin‐1 Autoimmune Nodopathy. Annals of Neurology. https://doi.org/10.1002/ana.27142
Vancouver
Caballero-Ávila M, Martín-Aguilar L, Pascual-Goñi E, Michael MR, Koel-Simmelink MJA, Höftberger R, et al. Long‐Term Follow Up in Anti‐Contactin‐1 Autoimmune Nodopathy. Annals of Neurology. 2025. doi:10.1002/ana.27142
BibTeX
@article{Caballerovila2025,
author = {Caballero-Ávila, Marta and Martín-Aguilar, Lorena and Pascual-Goñi, Elba and Michael, Milou R and Koel-Simmelink, Marleen J A and Höftberger, Romana and Wanschitz, Julia and Alonso-Jiménez, Alicia and Armangué, Thais and Baars, Adája Elisabeth and Carbayo, Álvaro and Castek, Barbara and Collet-Vidiella, Roger and De Winter, Jonathan and Del Real, Maria Ángeles and Delmont, Emilien and Diamanti, Luca and Doneddu, Pietro Emiliano and Hiew, Fu Liong and Gallardo, Eduard and Gonzalez, Amaia and Grinzinger, Susanne and Horga, Alejandro and Iglseder, Stephan and Jacobs, Bart C and Jauregui, Amaia and Killestein, Joep and Pozza, Elisabeth Lindeck and Martínez-Martínez, Laura and Nobile-Orazio, Eduardo and Ortiz, Nicolau and Pérez-Pérez, Helena and Poppert, Kai-Nicolas and Ripellino, Paolo and Roche, Jose Carlos and Rodriguez de Rivera, Franscisco Javier and Rostasy, Kevin and Sparasci, Davide and Tejada-Illa, Clara and Teunissen, Charlotte C E and Vegezzi, Elisa and Xuclà-Ferrarons, Tomàs and Zach, Fabian and Wieske, Luuk and Eftimov, Filip and Lleixà, Cinta and Querol, Luis},
title = {Long‐Term Follow Up in Anti‐Contactin‐1 Autoimmune Nodopathy},
journal = {Annals of Neurology},
year = {2025},
doi = {10.1002/ana.27142}
}
EUVIMED